PT  - JOURNAL ARTICLE
AU  - Lo Russo, Giuseppe
AU  - Prelaj, Arsela
AU  - Dolezal, James
AU  - Beninato, Teresa
AU  - Agnelli, Luca
AU  - Triulzi, Tiziana
AU  - Fabbri, Alessandra
AU  - Lorenzini, Daniele
AU  - Ferrara, Roberto
AU  - Brambilla, Marta
AU  - Occhipinti, Mario
AU  - Mazzeo, Laura
AU  - Provenzano, Leonardo
AU  - Spagnoletti, Andrea
AU  - Viscardi, Giuseppe
AU  - Sgambelluri, Francesco
AU  - Brich, Silvia
AU  - Miskovic, Vanja
AU  - Pedrocchi, Alessandra Laura Giulia
AU  - Trovo', Francesco
AU  - Manglaviti, Sara
AU  - Giani, Claudia
AU  - Ambrosini, Paolo
AU  - Leporati, Rita
AU  - Franza, Andrea
AU  - McCulloch, John
AU  - Torelli, Tommaso
AU  - Anichini, Andrea
AU  - Mortarini, Roberta
AU  - Trinchieri, Giorgio
AU  - Pruneri, Giancarlo
AU  - Torri, Valter
AU  - De Braud, Filippo
AU  - Proto, Claudia
AU  - Ganzinelli, Monica
AU  - Garassino, Marina Chiara
TI  - PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis
AID  - 10.1136/jitc-2023-006833
DP  - 2023 Jun 01
TA  - Journal for ImmunoTherapy of Cancer
PG  - e006833
VI  - 11
IP  - 6
4099  - http://jitc.bmj.com/content/11/6/e006833.short
4100  - http://jitc.bmj.com/content/11/6/e006833.full
SO  - J Immunother Cancer2023 Jun 01; 11
AB  - Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.